Handel nachbörslich: 10.10 0.15 +1.51%

Capricor Therapeutics Inc (CAPR)

Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten

Capricor Therapeutics Inc (CAPR)

Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten

FY2024 EPS Estimates for Capricor Therapeutics Inc (NASDAQ:CAPR) Lifted by Analyst - MarketBeat

Capricor to seek deramiocel’s FDA approval for DMD heart disease - Muscular Dystrophy News

High Growth Tech Stocks To Watch In September 2024 - Simply Wall St

H.C. Wainwright backs Capricor's regulatory shift for faster approval of deramiocel - Investing.com

Health Care Down Amid Fears of Lower Drug Profits -- Health Care Roundup - Marketscreener.com

H.C. Wainwright backs Capricor's regulatory shift for faster approval of deramiocel - Investing.com Canada

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump - Benzinga

Capricor stock target raised with consistent Buy rating from Maxim on FDA update - Investing.com Australia

Capricor stock target raised with consistent Buy rating from Maxim on FDA update - Investing.com Canada

Maxim Group Increases Capricor Therapeutics (NASDAQ:CAPR) Price Target to $25.00 - Defense World

Maxim Group Increases Capricor Therapeutics (NASDAQ:CAPR) Price Target to $25.00 - MarketBeat

Ready to Jump After Recent Trade: Capricor Therapeutics Inc (CAPR) - SETE News

why Capricor Therapeutics Inc [CAPR] is a Good Choice for Investors After New Price Target of $28.80 - The DBT News

Capricor surges on plans to seek FDA approval for lead asset - MSN

Capricor Therapeutics Inc. (NASDAQ:CAPR) Stock Rockets 53% On Heavy Volume: How To Trade Now? - DRP Journal

Capricor Therap stock soars to 52-week high of $8.43 By Investing.com - Investing.com Australia

Nvidia, Alibaba, Capricor Therapeutics, TSMC, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga

Wave Life And Capricor Surge Forward With HopeAre These Stocks In Your Portfolio? - RTTNews

Capricor Therapeutics Inc (NASDAQ:CAPR) Major Shareholder Shinyaku Co Ltd Nippon Acquires 2,798,507 Shares - Defense World

Health Care Stocks Fall as Novo Nordisk CEO Goes To Capitol Hill -- Health Care Roundup - Marketscreener.com

Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off (NASDAQ:CAPR) - Seeking Alpha

Nippon Shinyaku buys $15 million of Capricor Therapeutics stock - Investing.com

Capricor Therap stock soars to 52-week high of $8.43 By Investing.com - Investing.com Canada

Understanding the Risks and Rewards of Investing in Capricor Therapeutics Inc Inc. (CAPR) Based on Price Performance - The InvestChronicle

Capricor Therap stock soars to 52-week high of $8.43 - Investing.com

Evaluating CAPR’s financial ratios for a profitable investment - US Post News

Capricor (CAPR) Sees Stock Rise After Announcing BLA Submission Plans - Stocks Telegraph

HC Wainwright Reaffirms "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat

HC Wainwright Reaffirms “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR) - Defense World

Capricor stock surges on pipeline update (NASDAQ:CAPR) - Seeking Alpha

Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch

Capricor Therapeutics plans October BLA submission for DMD treatment - Investing.com

Capricor Therapeutics Announces Intent to File Biologics - GlobeNewswire

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy - Yahoo Finance

Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? - Yahoo Finance

Capricor to update on Duchenne therapy progress By Investing.com - Investing.com Canada

Capricor shares maintain Outperform rating from Oppenheimer By Investing.com - Investing.com Canada

Capricor shares maintain Outperform rating from Oppenheimer - Investing.com India

Capricor Therapeutics (NASDAQ:CAPR) Given Outperform Rating at Oppenheimer - MarketBeat

Capricor Therapeutics (NASDAQ:CAPR) Given Outperform Rating at Oppenheimer - Defense World

Capricor to update on Duchenne therapy progress - Investing.com

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024 - ForexTV.com

Capricor to update on Duchenne therapy progress By Investing.com - Investing.com UK

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024 - GlobeNewswire

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024 - StockTitan

Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy - Seeking Alpha

Capricor Therapeutics’ (CAPR) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World

Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga

Capricor Therapeutics' (CAPR) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat

Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $19.80 - Defense World

Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel - MSN

An analyst sees good growth prospects for Capricor Therapeutics Inc (CAPR) - SETE News

Capricor shares hold target, buy rating on expanded DMD deal By Investing.com - Investing.com Canada

Capricor Therapeutics (NASDAQ:CAPR) PT Raised to $15.00 at Oppenheimer - Defense World

Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 6.7% in August - Defense World

Capricor shares hold target, buy rating on expanded DMD deal - Investing.com

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28% - Simply Wall St

Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World

Capricor Therapeutics (NASDAQ:CAPR) Given “Buy” Rating at Maxim Group - Defense World

Capricor shares gain as Oppenheimer raises price target to $15 By Investing.com - Investing.com Canada

Capricor secures $35 million in funding for DMD treatment By Investing.com - Investing.com Canada

Capricor secures $35 million in funding for DMD treatment - Investing.com

Short Interest in Capricor Therapeutics Inc (NASDAQ:CAPR) Increases By 6.7% - MarketBeat

Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $19.80 Consensus Target Price from Brokerages - MarketBeat

Oppenheimer Boosts Capricor Therapeutics (NASDAQ:CAPR) Price Target to $15.00 - MarketBeat

Capricor shares gain as Oppenheimer raises price target to $15 - Investing.com

Capricor Therapeutics' (CAPR) Buy Rating Reiterated at Maxim Group - MarketBeat

Capricor rises as it expands deal with Nippon Shinyaku - The Pharma Letter

Capricor Therapeutics Shares Rise After Deramiocel Deal With Nippon Shinyaku - MarketWatch

CAPRCapricor Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Capricor Therapeutics Signs Binding Term Sheet with Nippon - GlobeNewswire

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - StockTitan

EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga

Capricor Therapeutics, Inc. announced that it has received $14.999998 million in funding from Nippon Shinyaku Co., Ltd. - Marketscreener.com

Ähnlich wie CAPR